Capstone (CAPS) Competitors $1.90 +0.14 (+7.95%) As of 05/1/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CAPS vs. PCSA, PTEIQ, ASLN, BPTH, CWBR, BPTSY, NMTR, TRVN, EVFM, and APVOShould you be buying Capstone stock or one of its competitors? The main competitors of Capstone include Processa Pharmaceuticals (PCSA), PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), Bio-Path (BPTH), CohBar (CWBR), Biophytis (BPTSY), 9 Meters Biopharma (NMTR), Trevena (TRVN), Evofem Biosciences (EVFM), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry. Capstone vs. Processa Pharmaceuticals PolarityTE ASLAN Pharmaceuticals Bio-Path CohBar Biophytis 9 Meters Biopharma Trevena Evofem Biosciences Aptevo Therapeutics Capstone (NASDAQ:CAPS) and Processa Pharmaceuticals (NASDAQ:PCSA) are both small-cap manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking. Does the MarketBeat Community prefer CAPS or PCSA? Processa Pharmaceuticals received 15 more outperform votes than Capstone when rated by MarketBeat users. CompanyUnderperformOutperformCapstoneN/AN/AProcessa PharmaceuticalsOutperform Votes1560.00% Underperform Votes1040.00% Does the media refer more to CAPS or PCSA? In the previous week, Processa Pharmaceuticals had 2 more articles in the media than Capstone. MarketBeat recorded 3 mentions for Processa Pharmaceuticals and 1 mentions for Capstone. Capstone's average media sentiment score of 1.89 beat Processa Pharmaceuticals' score of 0.44 indicating that Capstone is being referred to more favorably in the media. Company Overall Sentiment Capstone Very Positive Processa Pharmaceuticals Neutral Do insiders & institutionals believe in CAPS or PCSA? 2.5% of Capstone shares are owned by institutional investors. Comparatively, 91.9% of Processa Pharmaceuticals shares are owned by institutional investors. 42.8% of Capstone shares are owned by company insiders. Comparatively, 13.0% of Processa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend CAPS or PCSA? Processa Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 2,299.04%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Processa Pharmaceuticals is more favorable than Capstone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, CAPS or PCSA? Capstone has higher revenue and earnings than Processa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstone$44.05M0.01N/AN/AN/AProcessa PharmaceuticalsN/AN/A-$11.12M-$3.89-0.06 Which has more volatility & risk, CAPS or PCSA? Capstone has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Is CAPS or PCSA more profitable? Capstone's return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets CapstoneN/A N/A N/A Processa Pharmaceuticals N/A -195.21%-163.06% SummaryProcessa Pharmaceuticals beats Capstone on 7 of the 12 factors compared between the two stocks. Get Capstone News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstonePharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$300,000.00$6.84B$2.02B$7.93BDividend YieldN/A3.05%2.70%4.22%P/E RatioN/A7.3222.4718.54Price / Sales0.01241.4959.25103.30Price / CashN/A65.8551.7234.62Price / BookN/A6.481.994.25Net IncomeN/A$143.41M-$333.48M$248.18M7 Day Performance-5.47%2.58%0.49%1.03%1 Month Performance-19.49%5.00%-0.96%2.70%1 Year PerformanceN/A-3.72%7.77%4.05% Capstone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstoneN/A$1.90+8.0%N/AN/A$300,000.00$44.05M0.0038PCSAProcessa Pharmaceuticals2.9814 of 5 stars$0.24-0.7%$6.00+2,429.5%-88.7%$1.25MN/A-0.0720Upcoming EarningsNews CoverageGap DownPTEIQPolarityTEN/AN/AN/AN/A$1.24M$810,000.00-0.0560Gap UpASLNASLAN PharmaceuticalsN/A$0.60flat$72.00+11,900.0%N/A$1.23M$12M-0.0330BPTHBio-Path1.5388 of 5 stars$0.15-9.3%$20.00+13,693.1%-94.6%$1.21MN/A0.0010News CoverageCWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010BPTSYBiophytisN/A$3.36flatN/A-78.0%$1.18MN/A0.0030NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220TRVNTrevena0.8052 of 5 stars$1.20+3.0%$5.00+318.4%-87.2%$1.03M$443,000.00-0.0340EVFMEvofem BiosciencesN/A$0.01-1.1%N/A-38.6%$1.02M$11.39M-0.01120APVOAptevo Therapeutics2.6907 of 5 stars$0.67-2.4%$10,952.00+1,622,899.4%-100.0%$985,000.00$3.11M0.0050Upcoming EarningsGap Down Related Companies and Tools Related Companies PCSA Alternatives PTEIQ Alternatives ASLN Alternatives BPTH Alternatives CWBR Alternatives BPTSY Alternatives NMTR Alternatives TRVN Alternatives EVFM Alternatives APVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CAPS Stock Free CAPS Stock Alerts